01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. The Amplatzer duct occluder II additional sizes device for transcatheter PDA closure: Initial experience

Elchanan Bruckheimer MBBS,1,†,*, Max Godfrey BSc, MBBS,1,†, Tamir Dagan MD,1, Michael Levinzon MD,2, Gabriel Amir MD, PhD,3 andEinat Birk MD1

Objectives: To present our initial experience with the Amplatzer Duct Occluder II Additional Sizes (ADOIIAS) device.

01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Long-term clinical experience with amplatzer ductal occluder II for closure of the persistent arterial duct in children

Sok-Leng Kang MBBS, MRCPCH, Gareth Morgan MPhil, MRCPCH*, Jonathan Forsey MBChB, MRCPCH, Andrew Tometzki MB, FRCP andRobin Martin MB, FRCP, FRCPCH

Objectives: To describe the long-term clinical experience and follow-up with the Amplatzer Ductal Occluder II (ADO II) in children.

01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Outcomes of percutaneous coronary intervention of chronic total saphenous vein graft occlusions in the contemporary era

Nadish Garg MD, Abdul Hakeem MD, Freij Gobal MD andBarry F. Uretsky MD*

Background: Percutaneous coronary intervention of a chronic total occlusion to a saphenous vein graft is currently not recommended because the benefit/risk ratio is considered unfavorable. However, there is a patient subset with clinical ischemia, and PCI of the native chronic total occlusion (CTO) is unfavorable. In this setting, PCI to the saphenous vein graft (SVG) may have utility. We reviewed our experience to determine its value in the modern era.

01 junio 2014

AMERICAN HEART JOURNAL. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study

Guido Parodi, MD, Benedetta Bellandi, MD, Renato Valenti, MD, Angela Migliorini, MD, Rossella Marcucci, MD, Nazario Carrabba, MD, Letizia Giurlani, MD, Gian Franco Gensini, MD, Rosanna Abbate, MD, David Antoniucci, MD

Background: In ST-elevation myocardial infarction (STEMI) patients, residual platelet reactivity soon after a loading dose (LD) of prasugrel or ticagrelor is higher than that reported for healthy volunteers or subjects with stable coronary artery disease; and the majority of primary percutaneous coronary intervention (PPCI) procedures with bivalirudin monotherapy are performed without proper platelet inhibition. However, ticagrelor LD is just the daily dose, whereas prasugrel LD is 6-fold the long-term daily dose. We hypothesized that an increased ticagrelor LD may result in a faster and more effective platelet inhibition as compared with the standard prasugrel LD.

01 junio 2014

AMERICAN HEART JOURNAL. Ten-year clinical follow-up after sirolimus-eluting stent implantation

Nuno Palhais, MD, Diego Arroyo, MD, Sonja Lehmann, BSc, Mario Togni, MD, Urs Kaufmann, MD, Serban-Georges Puricel, MD, Jean-Christophe Stauffer, MD, Jean-Jacques Goy, MD, Stéphane Cook, MD

Background: Little is known on the “very” long-term incidence of major adverse cardiac events (MACE), target-lesion revascularization (TLR), target-vessel revascularization and stent thrombosis after sirolimus-eluting stent (SES) implantation. We present the first study to provide a 10-year clinical follow-up in an unselected patient population who underwent SES implantation.

01 junio 2014

AMERICAN HEART JOURNAL. Association between prehospital electrocardiogram use and patient home distance from the percutaneous coronary intervention center on total reperfusion time in ST-segment–elevation myocardial infarction patients: A retrospective analysis from the National Cardiovascular Data Registry

Bryn E. Mumma, MD, MAS, Michael C. Kontos, MD, S. Andrew Peng, MS, Deborah B. Diercks, MD, MSc

Background: Current guidelines recommend ≤90 minutes from first medical contact to percutaneous coronary intervention (FMC2B) for ST-segment–elevation myocardial infarction (STEMI) patients. We evaluated the relationship between patient home distance from a percutaneous coronary intervention (PCI) center, prehospital electrocardiogram (ECG) use, and FMC2B time among patients with STEMI.

29 abril 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Coronary Hemodynamics. Physiological Basis and Long-Term Clinical Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of Intermediate Severity

Tim P. van de Hoef, MD, Martijn A. van Lavieren, MSc, Peter Damman, MD, PhD, Ronak Delewi, MD, Martijn A. Piek, Steven A.J. Chamuleau, MD, PhD, Michiel Voskuil, MD, PhD, José P.S. Henriques, MD, PhD, Karel T. Koch, MD, PhD, Robbert J. de Winter, MD, PhD, Jos A.E. Spaan, PhD, Maria Siebes, PhD, Jan G.P. Tijssen, PhD, Martijn Meuwissen, MD, PhD and Jan J. Piek, MD, PhD

Background: Discordance between fractional flow reserve (FFR) and coronary flow velocity reserve (CFVR) may reflect important coronary pathophysiology but usually remains unnoticed in clinical practice. We evaluated the physiological basis and clinical outcome associated with FFR/CFVR discordance.

15 abril 2014

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Pharmacology. Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Non–ST-Segment–Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease. Results From the Evaluation of Drug-Eluting Stents and Ischemic Events Registry

Sripal Bangalore, MD, MHA, Michael J. Pencina, PhD, Neal S. Kleiman, MD and David J. Cohen, MD, MSc

Background: The use of bivalirudin versus unfractionated heparin monotherapy in patients without ST-segment–elevation myocardial infarction is not well defined.

01 julio 2014

JACC. Stent Thrombosis in New-Generation Drug-Eluting Stents in Patients With STEMI Undergoing Primary PCI. A Report From SCAAR

Giovanna Sarno, MD, PhD∗; Bo Lagerqvist, MD, PhD∗; Johan Nilsson, MD†; Ole Frobert, MD, PhD‡; Kristina Hambraeus, MD, PhD§; Christoph Varenhorst, MD, PhD∗; Ulf J. Jensen, MD‖; Tim Tödt, MD¶; Matthias Götberg, MD, PhD#; Stefan K. James, MD∗

Background: Some concerns still have not been resolved about the long-term safety of drug-eluting stents (DES) in patients with acute STEMI.

01 julio 2014

JACC. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy

David R. Holmes, MD∗; Saibal Kar, MD†; Matthew J. Price, MD‡; Brian Whisenant, MD§; Horst Sievert, MD‖; Shephal K. Doshi, MD¶; Kenneth Huber, MD#; Vivek Y. Reddy, MD∗∗

Background: In the PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) trial that evaluated patients with nonvalvular atrial fibrillation (NVAF), left atrial appendage (LAA) occlusion was noninferior to warfarin for stroke prevention, but a periprocedural safety hazard was identified.

01 julio 2014

JACC. Stent Thrombosis Following Drug-Eluting Stents in STEMI

Bradley H. Strauss, MD, PhD; Mony Shuvy, MD

Coronary stent implantation has become the mainstay of percutaneous revascularization in patients with stable coronary artery disease (CAD) and acute coronary syndromes (ACS). Bare metal stents (BMS) were widely adopted after they were demonstrated to decrease restenosis and acute vessel occlusion compared with balloon angioplasty, although the thrombosis risk was <1% and usually occurred within the first month after implantation (1).

15 julio 2014

INTERNATIONAL JOURNAL OF CARDIOLOGY. Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES

Giuseppe De Luca, Maurits T. Dirksen, Christian Spaulding, Henning Kelbæk, Martin Schalij, Leif Thuesen, Bas van der Hoeven, Marteen A. Vink, Christoph Kaiser, Carmine Musto, Tania Chechi, Gaia Spaziani, Luis Salvador Diaz de la Llera, Vincenzo Pasceri, Emilio Di Lorenzo, Roberto Violini, Harry Suryapranata, Gregg W. Stone, for the DESERT cooperation

Background: Hypertension is a well known risk factor for atherosclerosis. However, data on the prognostic impact of hypertension in patients with ST elevation myocardial infarction (STEMI) are inconsistent and mainly related to studies performed in the thrombolytic era, with very few data in patients undergoing primary angioplasty. Therefore, the aim of the current study was to evaluate the impact hypertension on clinical outcome in STEMI patients undergoing primary PCI with BMS or DES.

15 julio 2014

INTERNATIONAL JOURNAL OF CARDIOLOGY. Cognitive dysfunction follows left heart catheterisation but is not related to microembolic count

David A. Scott1, Lisbeth A. Evered1, Richard P. Gerraty1, Andrew MacIsaac1, Julia Lai-Kwon1, Brendan S. Silbert1

Background: Left heart catheterisation with coronary angiography (CA) may lead to cognitive dysfunction, as a result of neurological injury. The aim was to assess the incidence of cognitive dysfunction in elderly patients three months after CA and investigate any association between cognitive dysfunction and microembolic count during CA.

15 julio 2014

INTERNATIONAL JOURNAL OF CARDIOLOGY. Use of covered Cheatham-Platinum stents in congenital heart diseas

Ward Y. Vanagt1, Björn Cools2, Derize E. Boshoff1, Stefan Frerich2, Ruth Heying1, Els Troost2, Jacoba Louw2, Benedicte Eyskens1, Werner Budts1, Marc Gewillig1

Background: Controversy remains regarding the use of covered stents in congenital heart disease (CHD). We evaluate the possibilities and safety of covered Cheatham-Platinum (CCP) stents in CHD.

15 julio 2014

INTERNATIONAL JOURNAL OF CARDIOLOGY. Trend in the use of drug eluting stents in the United State

Sripal Bangalore, Navdeep Gupta, Yu Guo, Frederick Feit

Background: Drug eluting stents (DES) reduce the risk of restenosis but are associated with increase in the risk of very late stent thrombosis, especially when antiplatelet therapy is held. The trend in DES use across the US is not fully defined.